Genetic epidemiology of BRCA mutations - family history detects less than 50% of the mutation carriers

European Journal of Cancer

Volumn 43, Issue 11, 2007, Pages 1713-1717

  Møller, Pål ^a   Hagen, Anne Irene ^b   Apold, Jaran ^c,d   Maehle, Lovise ^a   Clark, Neal ^a   Fiane, Bent ^e   Løvslett, Kjell ^e   Hovig, Eivind ^a   Vabø, Anita ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

BRCA1; BRCA2; Breast cancer; Founder mutations; Genetic epidemiology; Genetic testing; Incident cancers; Ovarian cancer

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; FAMILY HISTORY; FEMALE; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NORWAY; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; NORWAY; OVARIAN NEOPLASMS; PEDIGREE;

EID: 34447298637     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.04.023     Document Type: Article

References (15)

1. Heimdal K., Maehle L., Apold J., Pedersen J.C., and Moller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 39 15 (2003) 2205-2213
2. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 orBRCA2 mutations. N Engl J Med 346 21 (2002) 1616-1622
3. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 andBRCA2 mutation carriers: an international case-control study. J Clin Oncol 23 30 (2005) 7491-7496
4. Rebbeck T.R., Friebel T., Wagner T., et al. Effect of Ssort-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 andBRCA2 mutation carriers: The PROSE study group. J Clin Oncol 23 31 (2005) 7804-7810
5. Møller P., Borg Å., Evans D.G., et al. Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101 (2002) 555-559
6. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 andBRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22 6 (2004) 1055-1062
7. Moller P., Evans G., Haites N., et al. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Dis Markers 15 1-3 (1999) 207-211
8. Bodd T.L., Reichelt J., Heimdal K., and Moller P. Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway. J Genet Couns 12 5 (2003) 405-417
9. Lubinski J., Górski B., Huzarski T., et al. BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99 1 (2006) 71-76
10. Gronwald J., Huzarski T., Byrski T., et al. Direct-to-patient BRCA1 testing: the Twoj Styl experience. Breast Cancer Res Treat 100 3 (2006) 239-245
11. Møller P., Borg A., Heimdal K., et al. TheBRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series. Eur J Cancer 37 (2001) 1027-1032
12. Kotar K., Brunet J.S., Møller P., et al. Ratio of female to male offspring of women tested for BRCA1 andBRCA2 mutations. J Med Genet 41 8 (2004) e103
13. Cancer Registry of Norway. Breast females. Cancer in Norway. Cancer Registry of Norway (2004), Cancer Registry of Norway, Oslo
14. NOU. Å vite eller ikke å vite. Gentester ved arvelig kreft. Norwegian Government (1999), NOU, Oslo, Norway p.20
15. Moller P., Heimdal K., Apold J., et al. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 37 18 (2001) 2428-2434